While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires further research for wider adoption.
The slow pace of financing in med-tech appears to have stimulated cardiac arrhythmia technology developer Adagio Medical Inc. to turn to a special purpose acquisition company (SPAC) in a type of deal that has all but vanished in the last year. The company signed an agreement with Arya Sciences Acquisition Corp. IV to combine in a reverse merger deal that will result in Adagio’s listing on Nasdaq under “ADGM.”
Cryoablation, a minimally invasive technique to target and kill tumors, continues gaining traction in the medical field and with patients. Compared to surgical
In the ADVENT trial, pulsed field ablation, a new technology for terminating drug-refractory paroxysmal AF, was noninferior to conventional thermal ablation but had potential advantages.